This page shows the details of why an item matched the keywords from your search.
| Item Type | Name |
|
Academic Article
|
Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.
|
|
Academic Article
|
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
|
|
Academic Article
|
Fifty years of melphalan use in hematopoietic stem cell?transplantation.
|
|
Academic Article
|
Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.
|
|
Academic Article
|
Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells
|
|
Academic Article
|
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.
|
|
Academic Article
|
Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.
|
|
Academic Article
|
Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome.
|
|
Academic Article
|
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ? Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.
|
|
Concept
|
Bortezomib
|
|
Academic Article
|
Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance.
|
|
Academic Article
|
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma.
|